A systematic review of the effectiveness of adalimumab

The contents remain the responsibility of the
authors and Amanda Burls is guarantor. They
are grateful to the following individuals for their
help or advice during the writing of this report:
Linda Briscoe (Department of Public Health and
Epidemiology, University of Birmingham), Becky
Taylor (Health Economics Facility, University of
Birmingham), Drs Renée Allaart and Yvonne
Goekoop-Ruiterman (Leiden University Medical
Center, The Netherlands), Dr Jeska de Vries-
Bouwstra (VU Medical Center, Amsterdam, The
Netherlands), and other BeSt study investigators
for providing prepublication manuscript from the
BeSt study, Professor Tom Huizinga (Leiden
University Medical Center, The Netherlands), for
facilitating initial communication, David Fisher, Dr
Nigel Arden, Dr Chris Edwards and Dr Tjeerd van
Staa (MRC Epidemiology Resource Centre,
University of Southampton), for providing GPRD
data on DMARD use in the UK, Peter Conway and
Alan Reynolds (Wyeth Laboratories UK), for
providing additional data from etanercept trials,
Alan Kane (Schering-Plough UK), for providing
additional data from infliximab trials, Abbott
Laboratories, for providing additional data from
adalimumab trials, and the peer reviewers for
their useful comments.
This report was commissioned by the NHS R&D
HTA Programme.
Contribution of authors
Pelham Barton (Lecturer in Mathematical
Modelling) constructed and analysed the new
version of the Birmingham Rheumatoid Arthritis
Model (BRAM), drafted the section of the report
relating to the BRAM, responded to peer review,
and read and edited the draft report. Stirling
Bryan (Professor in Health Economics) selected
Acknowledgements
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
studies from the searches for published economic
analyses, contributed to the economics review,
review of submissions from industry, development
of model structure and unit cost data collection,
and edited the report. Amanda Burls (Senior
Clinical Lecturer in Public Health and
Epidemiology) was the senior reviewer on this
report and provided project management and
advice on all aspects of the report, participated in
data extraction and analyses, drafted the results
section, summary and discussion, compiled and
edited the draft report, and takes final
responsibility for the whole report. Yen-Fu Chen
(Systematic Reviewer) was the main reviewer on
this report and maintained day-to-day running of
the review. He compiled the study protocol,
carried out study selection and data extraction
(mainly for etanercept and infliximab), and
conducted meta-analyses. He also drafted the
following sections: methods, narratives for
included trials, and part of the results and
discussion, and edited the report. Wendy Clark
(Information Pharmacist) applied the inclusion
and exclusion criteria, was involved in data
extraction principally for adalimumab, and
commented on the draft report. Anne Fry-Smith
(Information Specialist) devised and implemented
search strategies for bibliographic databases,
drafted the searching methods section and
commented on the draft report. Paresh
Jobanputra (Consultant Rheumatologist) drafted
the introduction, assisted with study selection,
extracted data from some studies, contributed to
the development of the economic model,
identified data sources for parameters for the
model, edited the report and responded to
peer-review comments. Sue Jowett (Health
Economist) wrote the review of existing economic
evaluations.
125